ABOUT: Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
![](https://wallstreetanalyzer.com/wp-content/uploads/2022/12/Unknown-3.png)
![](https://wallstreetanalyzer.com/wp-content/uploads/2022/12/RFV-Photo-878x1024.jpg)
THIS INTERVIEW HAS EXPIRED